Needham & Company Reiterates Buy on Progenics Pharma (PGNX); Anticipates Oral Relistor Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results
March 11, 2016 8:00 AM ESTRELISTOR® Net Sales Increased to $23.0 Million for the Fourth Quarter Oral RELISTOR Remains On-track for April 19, 2016 PDUFASubcutaneous RELISTOR Approved in Europe for All Opioid-Induced ConstipationAZEDRA® Ultra-Orphan Cancer Therapeutic Receives FDA Breakthrough DesignationAZEDRA Completes Enrollment of 68 Patients in Pivotal Trial and Topline Results Expected Between December 2016 and March 2017Initiated Pivotal Phase 3 Study of 1404, PSMA-Targeted SPECT/CT Imaging Agent Clinical Studies Planned for PyL PSMA-Targeted PET/CT Imaging Agent Licensed... More
